中文 English

Singlera Genomics hosts satellite meeting at the 2016 Chinese Medical Association Pathology Conference

November 25-27, 2016 – Hefei, Anhui, China
The 22nd academic conference of the Chinese Medical Association Pathology Branch and the 6th session of the Chinese Pathology Annual Meeting was held in Hefei, Anhui, China. Singlera Genomics, Inc. participated in the conference and shared the latest corporate achievements in next generation sequencing (NGS) techniques for pathologic diagnosis with pathologists, doctors and technologists.
Satellite meeting: NGS Technology Leads Pathology into the Era of Precision Medicine
During the conference, Singlera Genomics hosted the satellite meeting “NGS Technology Leads Pathology into the Era of Precision Medicine”, attended by more than 200 pathologists from throughout China. The meeting was convened by Hong Bu from West China Hospital of Sichuan University and Bo Zhang from Beijing University Health Science Center. The first lecture “Prevention and Screening of Hereditary Breast Cancer in China”, presented by Mei Liu from PLA General Hospital (301 Hospital), discussed the prevalence of hereditary breast cancer in China and introduced the importance of multi-gene detection for BRCA1, BRCA2, TP53 and CHEK2 in screening tests for hereditary breast cancer. Feng Ye from West China Hospital of Sichuan University presented the lecture “Pathology experts’ consensus on NGS” from the perspective of technical practice, which allowed participants to systematically oversee the requirements of NGS being used in the pathology department including NGS technical processes, sampling and diagnostic conditions. Rui Liu, CTO of Singlera Genomics, introduced the unique advantages of Singlera Genomics’ patented NGS techniques for handling low volume samples and detecting ctDNA. Singlera Genomics’ NGS techniques feature high sensitivity and sample robustness while reducing background noise and enabling detection of methylation levels.
After the lectures, all panelists participated in a roundtable discussion and enthusiastically offered their opinions of how NGS technology will be developed and utilized within pathology departments. The panelists universally believed that NGS technologies have become important diagnostic tools for molecular pathology. Furthermore, they remarked it is inevitable that pathology departments will need to oversee NGS testing and the pathology department should be the first choice for running ctDNA diagnostics or multi-gene detection on tissue samples within hospitals. Accordingly, this oversight will usher the field of pathology into the booming era of precision medicine.
Singlera Genomics presents preliminary results of NGS multi-center study
The NGS multi-center study “Multi-center Clinical Validation of NGS Detection” is the first such study in China. The study is overseen by the Chinese Medical Association Pathology Branch, organized by the West China Hospital pathology department, and sponsored by Singlera Genomics. Twelve hospitals throughout China are participating in the study. Singlera Genomics disclosed preliminary results for the study on the morning of November 25, 2016. The multi-center study has been operating smoothly for five months, during which most participating hospitals have completed case collections, trained on NGS operations, extracted sample DNA and performed bench sequencing for many samples. All phases of the study have been running without complications and the data collection is analytically sound.
Professors Hong Bu, Zhiyong Liang, Bo Zhang, Xiaoyan Zhou, Huaiying Shi and other experts joined the meeting discussion and representatives from the twelve hospitals (West China Hospital of Sichuan University, Peking Union Medical College Hospital, No.3 Hospital of Peking University, General Hospital of PLA (301 Hospital), the Tumour Hospital Affiliated to Fudan University, Zhongshan Hospital Affiliated to Fudan University, Nanfang Hospital Affiliated to Southern Medical University, Wuhan Tongji Hospital, the First Affiliated Hospital of Zhejiang University Medical College, Jiangsu Province People's Hospital, Fujian Tumor Hospital and the First Affiliated Hospital of Zhengzhou University) presented at the meeting. Feng Ye of the West China Hospital of Sichuan University released a report of the available results to-date and Sanpeng Xu from Tongji Hospital of Huazhong University of Science and Technology shared his experiences with the study’s progress.
To date, the multi-center study has provided much valuable data. For example, the DNA archival quality from an FFPE sample can be up to 500 bp of DNA fragments, the pathology microscopic evaluation for tumor content in a sample should be more than 20%, the minimum allele frequency threshold is 5% and the average sequencing depth ranges from 500X-1000X. Consequently, the accumulation of additional data from the study is expected to provide fundamental answers to directly support the application of NGS techniques in hospitals and promote the development of precision medicine for oncology in China.
Singlera Genomics’ exhibitor booth
Singlera Genomics’ high-tech booth design with interactive games attracted large numbers of pathologists from around China. Booth visitors received information about Singlera’s technologies and participated in professional exchange and discussion.

返 回